Expression analysis of dopaminergic neurons in Parkinson’s disease and aging links transcriptional dysregulation of energy metabolism to cell death

[1]  Paul T. Schumacker,et al.  Oxidant stress evoked by pacemaking in dopaminergic neurons is attenuated by DJ-1 , 2010, Nature.

[2]  Manuel B. Graeber,et al.  PGC-1α, A Potential Therapeutic Target for Early Intervention in Parkinson’s Disease , 2010, Science Translational Medicine.

[3]  R. Rossignol,et al.  Multi-site control and regulation of mitochondrial energy production. , 2010, Biochimica et biophysica acta.

[4]  B. Yankner,et al.  Neural mechanisms of ageing and cognitive decline , 2010, Nature.

[5]  Fabienne C. Fiesel,et al.  PINK1/Parkin-mediated mitophagy is dependent on VDAC1 and p62/SQSTM1 , 2010, Nature Cell Biology.

[6]  David S. Park,et al.  DJ-1 protects the nigrostriatal axis from the neurotoxin MPTP by modulation of the AKT pathway , 2010, Proceedings of the National Academy of Sciences.

[7]  Ming Yi,et al.  Evidence for Gender-Specific Transcriptional Profiles of Nigral Dopamine Neurons in Parkinson Disease , 2010, PloS one.

[8]  Lloyd A Greene,et al.  Rapamycin Protects against Neuron Death in In Vitro andIn Vivo Models of Parkinson's Disease , 2010, The Journal of Neuroscience.

[9]  Atsushi Tanaka,et al.  PINK1 Is Selectively Stabilized on Impaired Mitochondria to Activate Parkin , 2010, PLoS biology.

[10]  Suzanne Timmons,et al.  Akt signal transduction dysfunction in Parkinson's disease , 2009, Neuroscience Letters.

[11]  I. McKeith,et al.  Single‐cell expression profiling of dopaminergic neurons combined with association analysis identifies pyridoxal kinase as Parkinson's disease gene , 2009, Annals of neurology.

[12]  A. Whitworth,et al.  Rapamycin activation of 4E-BP prevents parkinsonian dopaminergic neuron loss , 2009, Nature Neuroscience.

[13]  M. Beal,et al.  Inhibition of Prolyl Hydroxylase Protects against 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Neurotoxicity , 2009, The Journal of Biological Chemistry.

[14]  F. Benes,et al.  Gene expression profiling of substantia nigra dopamine neurons: further insights into Parkinson's disease pathology. , 2009, Brain : a journal of neurology.

[15]  T. Gasser.  Molecular pathogenesis of Parkinson disease: insights from genetic studies , 2009, Expert Reviews in Molecular Medicine.

[16]  C. D. Rollo.  Dopamine and Aging: Intersecting Facets , 2009, Neurochemical Research.

[17]  Christine A. Wells,et al.  A Cross-Study Transcriptional Analysis of Parkinson's Disease , 2009, PloS one.

[18]  Anastasia Kralli,et al.  Transcriptional control of mitochondrial biogenesis and function. , 2009, Annual review of physiology.

[19]  David S. Park,et al.  DJ-1/PARK7 is an important mediator of hypoxia-induced cellular responses , 2009, Proceedings of the National Academy of Sciences.

[20]  C. Kruse,et al.  Analysis of Gene Expression in Parkinson's Disease: Possible Involvement of Neurotrophic Support and Axon Guidance in Dopaminergic Cell Death , 2009, Brain pathology.

[21]  C. Klinge,et al.  Estrogenic control of mitochondrial function and biogenesis , 2008, Journal of cellular biochemistry.

[22]  J. Taylor,et al.  Autophagy and the ubiquitin-proteasome system: collaborators in neuroprotection. , 2008, Biochimica et biophysica acta.

[23]  T. Vanitallie.  Parkinson disease: primacy of age as a risk factor for mitochondrial dysfunction. , 2008, Metabolism: clinical and experimental.

[24]  Tianhong Pan,et al.  Neuroprotection of rapamycin in lactacystin-induced neurodegeneration via autophagy enhancement , 2008, Neurobiology of Disease.

[25]  R. Swerdlow,et al.  Mitochondria and ubiquitin-proteasomal system interplay: relevance to Parkinson's disease. , 2008, Free radical biology & medicine.

[26]  G. López-Lluch,et al.  Mitochondrial biogenesis and healthy aging , 2008, Experimental Gerontology.

[27]  A. Elbaz,et al.  Update in the epidemiology of Parkinson's disease , 2008, Current opinion in neurology.

[28]  M. Elstner,et al.  Dopaminergic midbrain neurons are the prime target for mitochondrial DNA deletions , 2008, Journal of Neurology.

[29]  S. Mandel,et al.  Genomic aspects of sporadic Parkinson's disease. , 2008, Parkinsonism & related disorders.

[30]  M. Graeber,et al.  Twenty-first century brain banking: at the crossroads , 2008, Acta Neuropathologica.

[31]  Susan M. Resnick,et al.  Morphometry of the human substantia nigra in ageing and Parkinson’s disease , 2008, Acta Neuropathologica.

[32]  K. Nakashima,et al.  Caffeine activates the PI3K/Akt pathway and prevents apoptotic cell death in a Parkinson's disease model of SH-SY5Y cells , 2008, Neuroscience Letters.

[33]  L. Moran,et al.  Towards a pathway definition of Parkinson’s disease: a complex disorder with links to cancer, diabetes and inflammation , 2008, Neurogenetics.

[34]  D. Surmeier,et al.  Calcium, ageing, and neuronal vulnerability in Parkinson's disease , 2007, The Lancet Neurology.

[35]  Stanley J. Watson,et al.  Methodological considerations for gene expression profiling of human brain , 2007, Journal of Neuroscience Methods.

[36]  P. Geiger,et al.  Calcium Induces Increases in Peroxisome Proliferator-activated Receptor γ Coactivator-1α and Mitochondrial Biogenesis by a Pathway Leading to p38 Mitogen-activated Protein Kinase Activation* , 2007, Journal of Biological Chemistry.

[37]  D. James Surmeier,et al.  ‘Rejuvenation’ protects neurons in mouse models of Parkinson’s disease , 2007, Nature.

[38]  M. Frosch,et al.  Effects of gender on nigral gene expression and parkinson disease , 2007, Neurobiology of Disease.

[39]  D. Maraganore,et al.  A Genomic Pathway Approach to a Complex Disease: Axon Guidance and Parkinson Disease , 2007, PLoS genetics.

[40]  M. Graeber,et al.  Glial degeneration and reactive gliosis in alpha-synucleinopathies: the emerging concept of primary gliodegeneration , 2006, Acta Neuropathologica.

[41]  R. Myers,et al.  Mitochondrial-related gene expression changes are sensitive to agonal-pH state: implications for brain disorders , 2006, Molecular Psychiatry.

[42]  T. Klockgether,et al.  Transcriptional changes in multiple system atrophy and Parkinson's disease putamen , 2006, Experimental Neurology.

[43]  L. Moran,et al.  Transcriptome analysis reveals link between proteasomal and mitochondrial pathways in Parkinson’s disease , 2006, Neurogenetics.

[44]  M. Onofrj,et al.  Diagnosis and management of dementia with Lewy bodies: Third report of the DLB Consortium , 2006, Neurology.

[45]  M. Cookson,et al.  Intersecting pathways to neurodegeneration in Parkinson's disease: Effects of the pesticide rotenone on DJ-1, α-synuclein, and the ubiquitin–proteasome system , 2006, Neurobiology of Disease.

[46]  Robert W. Taylor,et al.  High levels of mitochondrial DNA deletions in substantia nigra neurons in aging and Parkinson disease , 2006, Nature Genetics.

[47]  M. Farrer.  Genetics of Parkinson disease: paradigm shifts and future prospects , 2006, Nature Reviews Genetics.

[48]  N. Wood,et al.  Expanding insights of mitochondrial dysfunction in Parkinson's disease , 2006, Nature Reviews Neuroscience.

[49]  T. Kaysser-Kranich,et al.  Robust dysregulation of gene expression in substantia nigra and striatum in Parkinson's disease , 2006, Neurobiology of Disease.

[50]  L. Moran,et al.  Whole genome expression profiling of the medial and lateral substantia nigra in Parkinson’s disease , 2006, Neurogenetics.

[51]  John D. Storey,et al.  A network-based analysis of systemic inflammation in humans , 2005, Nature.

[52]  F. Middleton,et al.  Transcriptional analysis of multiple brain regions in Parkinson's disease supports the involvement of specific protein processing, energy metabolism, and signaling pathways, and suggests novel disease mechanisms , 2005, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[53]  R. Jensen,et al.  Expression profiling of substantia nigra in Parkinson disease, progressive supranuclear palsy, and frontotemporal dementia with parkinsonism. , 2005, Archives of neurology.

[54]  C. Tanner,et al.  Parkinsonian signs and substantia nigra neuron density in decendents elders without PD , 2004, Annals of neurology.

[55]  I. Ferrer,et al.  DNA Chip Technology in Brain Banks: Confronting a Degrading World , 2004, Journal of neuropathology and experimental neurology.

[56]  S. Mandel,et al.  Gene expression profiling of parkinsonian substantia nigra pars compacta; alterations in ubiquitin-proteasome, heat shock protein, iron and oxidative stress regulated proteins, cell adhesion/cellular matrix and vesicle trafficking genes , 2004, Journal of Neural Transmission.

[57]  B. Pakkenberg,et al.  Histological changes of the dopaminergic nigrostriatal system in aging , 2004, Cell and Tissue Research.

[58]  I. Kohane,et al.  Gene regulation and DNA damage in the ageing human brain , 2004, Nature.

[59]  Jonathan Pevsner,et al.  Progress in the use of microarray technology to study the neurobiology of disease , 2004, Nature Neuroscience.

[60]  H. Aburatani,et al.  A Novel Mitochondrial Carnitine-acylcarnitine Translocase Induced by Partial Hepatectomy and Fasting* , 2003, Journal of Biological Chemistry.

[61]  W. Dauer,et al.  Parkinson's Disease Mechanisms and Models , 2003, Neuron.

[62]  H. Braak,et al.  Staging of brain pathology related to sporadic Parkinson’s disease , 2003, Neurobiology of Aging.

[63]  B. Pakkenberg,et al.  Ageing of substantia nigra in humans: 
cell loss may be compensated by hypertrophy , 2002, Neuropathology and applied neurobiology.

[64]  K. Morikawa,et al.  Acetyl-CoA Synthetase 2, a Mitochondrial Matrix Enzyme Involved in the Oxidation of Acetate* , 2001, The Journal of Biological Chemistry.

[65]  A. Lees,et al.  Ageing and Parkinson's disease: substantia nigra regional selectivity. , 1991, Brain : a journal of neurology.

[66]  P. Riederer,et al.  Strategies for the protection of dopaminergic neurons against neurotoxicity , 2009, Neurotoxicity Research.

[67]  C. Altar,et al.  Target Identification for CNS Diseases by Transcriptional Profiling , 2009, Neuropsychopharmacology.

[68]  M. Elstner,et al.  The mitochondrial proteome database: MitoP2. , 2009, Methods in enzymology.

[69]  T. Meitinger,et al.  Chapter 1 The Mitochondrial Proteome Database , 2009 .